Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9275744 | 0.90 | TSHR (0.51) | TSHRHSD17B10POLBALOX15HTT | |
| SCHEMBL10111303 | 0.85 | CREBBP (0.53) | TSHRHSD17B10HTTNCOA1NCOA3 | |
| SCHEMBL2664838 | 0.84 | PLA2G2A (0.54) | TSHR | |
| SCHEMBL1515929 | 0.82 | TSHR (0.59) | TSHRHSD17B10POLBALOX15HTT | |
| SCHEMBL504156 | 0.82 | TSHR (0.70) | TSHRPOLBALOX15HTTLMNA | |
| SCHEMBL9048230 | 0.82 | CA12 (0.62) | TSHRHSD17B10POLBALOX15HTT | |
| SCHEMBL29633638 | 0.82 | TSHR (0.59) | TSHRHSD17B10POLBALOX15HTT | |
| SCHEMBL731013 | 0.81 | LMNA (0.50) | TSHRHSD17B10POLBNCOA1NCOA3 | |
| SCHEMBL12603750 | 0.81 | EGFR (0.48) | TSHRHSD17B10POLBHTTCA12 | |
| SCHEMBL289285 | 0.81 | CA12 (0.55) | TSHRHSD17B10NCOA1NCOA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| CN-119823001-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| CN-114206832-B | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-04 | — | — | CN | disclosed |
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4008405-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| CN-114206832-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-9447028-B2 | Therapeutic aryl-amido-aryl compounds and their use | KING'S COLLEGE LONDON (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2016-02-11 | — | — | US | disclosed |
| EP-2307422-B1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | MSD KK (JP) | 2014-03-26 | — | — | EP | disclosed |
| EP-2307422-B1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | MSD KK (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20110077262-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | MSD K.K. (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110077262-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | MSD K.K. (JP) | 2011-03-31 | — | — | US | disclosed |
| WO-2011027106-A1 | THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010002010-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-01-07 | — | — | WO | disclosed |
| EP-2120569-A2 | SPIROCHROMANON DERIVATIVES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | TSHR 733/4885HSD17B10 2545/4885POLB 4112/4885 |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | AKR1C3, CBR3, AKR1C4 | TSHR 680/4885HSD17B10 855/4885POLB 3207/4885 |
| US-20230097871-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | LPAR1, LPAR2, LPAR3 | TSHR 733/4885HSD17B10 2545/4885POLB 4112/4885 |
| US-20110077262-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | CNKSR1, CBR1, CBR3 | TSHR 932/4885HSD17B10 228/4885POLB 3574/4885 |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | TSHR 704/4885HSD17B10 882/4885POLB 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.